- Home
- OM vs CRVO Comparison
OM vs CRVO Comparison
Compare OM & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.40
HOLD
Current Price
$7.97
Company Overview
Basic Information| Metric | OM | CRVO |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 78.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OM | CRVO |
|---|---|---|
| Price | $3.40 | $7.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.00 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 496.7K | 52.8K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,069,000.00 | $6,159,786.00 |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $9.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $3.10 | $1.92 |
| 52 Week High | $25.35 | $16.94 |
Technical Indicators
Market Signals| Indicator | OM | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 23.48 | 45.85 |
| Support Level | $3.66 | $7.29 |
| Resistance Level | $3.83 | $8.55 |
| Average True Range (ATR) | 0.27 | 0.47 |
| MACD | 0.19 | -0.07 |
| Stochastic Oscillator | 18.36 | 41.77 |
Price Performance
Historical Comparison OM
CRVO
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.